Director/Board Member	10/03/2015	30/04/2018
Chief Executive Officer	30/04/2015	30/04/2018
Chief Operating Officer	08/02/2014	07/05/2015
President	13/01/2015	30/04/2018

Tony Chambers

Sales & Marketing

01/08/2015

01/04/2018

Brian Adams

General Counsel	15/04/2014	13/03/2018
Corporate Secretary	15/04/2014	13/03/2018

Helen Milton

General Counsel

01/09/2014

01/05/2017

Michael Tarnok

Director/Board Member	21/09/2007	24/04/2009
Chief Executive Officer	24/04/2009	20/05/2009
Chairman	24/04/2009	25/05/2016
Independent Dir/Board Member	21/09/2007	25/05/2016
President	24/04/2009	25/05/2009

Jack Kaye

Director/Board Member	19/09/2006	25/05/2016
Independent Dir/Board Member	19/09/2006	25/05/2016

Wyche Fowler

Director/Board Member	07/11/2006	25/05/2016
Independent Dir/Board Member	07/11/2006	25/05/2016

Joseph Feczko

Director/Board Member	16/07/2010	25/05/2016
Independent Dir/Board Member	16/07/2010	25/05/2016

William Gray

Comptroller/Controller/Auditor

01/09/2013

01/02/2016

Abraham Ceesay

Sales & Marketing

20/02/2014

02/01/2016

Enrique Poradosu

Chief Tech/Sci/R&D Officer

01/01/2003

01/01/2016

James Oliviero

Comptroller/Controller/Auditor	01/05/2003	17/04/2015
Director of Finance/CFO	01/04/2009	01/09/2015
Corporate Secretary	01/05/2003	17/04/2015
Treasurer	01/05/2003	01/09/2015

Ron Bentsur

Director/Board Member	16/06/2009	30/04/2015
Chief Executive Officer	20/05/2009	30/04/2015
Director of Finance/CFO	-	20/05/2009

Douglass H. Laidlaw

Chief Tech/Sci/R&D Officer

02/10/2013

Amit Sharma

Chief Tech/Sci/R&D Officer

13/03/2013

Kenneth Hoberman

Corporate Officer/Principal

01/01/2004

01/01/2012

Sean Power

Comptroller/Controller/Auditor

01/01/2006

31/08/2011

Constance Ames

Comptroller/Controller/Auditor

01/01/2010

Michael Weiss

Chief Executive Officer	01/01/2002	23/04/2009
Chairman	01/01/2002	23/04/2009

Mark Stier

Comptroller/Controller/Auditor	30/06/2008	30/06/2008
Director of Finance/CFO	30/06/2008	30/06/2008
Treasurer	30/06/2008	30/06/2008

Beth Levine

Compliance Officer	18/04/2007	27/06/2008
General Counsel	18/04/2007	27/06/2008
Corporate Secretary	18/04/2007	27/06/2008

I. Craig Henderson

President

01/02/2004

15/04/2008

William Kane

Corporate Officer/Principal

17/07/2007

Ronald Renaud

Director of Finance/CFO	01/02/2006	01/05/2007
Treasurer	01/02/2006	01/05/2007

Lindsay Rosenwald

Director/Board Member	01/03/2000	01/11/2006
Founder	01/01/1994	01/11/2006

Eric Rose

Director/Board Member

01/08/2004

BILL Kessler

Comptroller/Controller/Auditor

01/01/2001

01/09/2003

Scott A. Holmes

Comptroller/Controller/Auditor	01/01/2003	01/01/2003
Comptroller/Controller/Auditor	27/07/2015	12/12/2018
Director of Finance/CFO	27/07/2015	12/12/2018
Treasurer	-	12/12/2018

Morris Laster

Chief Executive Officer	01/01/1997	01/01/2002
Chairman	01/01/1997	01/01/2002

Malcolm Hoenlein

Director/Board Member

01/01/2001

Peter Salomon

Director/Board Member

Lawrence J. Kessel

Director/Board Member

Ira Weinstein

Chief Operating Officer	-	-
Director of Finance/CFO	-	-

Peter Morgan Kash

Director/Board Member	-	-
Founder	-	-

Robert Niecestro

Corporate Officer/Principal

Martin Burg

Chief Administrative Officer	-	-
Human Resources Officer	-	-

Robert Trachtenberg

General Counsel

Robert Gallahue

Director of Finance/CFO

Eric Grossman

Corporate Officer/Principal

Lauren Fischer

Investor Relations Contact

Shmuel A. Ben-Sasson

Corporate Officer/Principal

Ivan Bergstein

Chief Tech/Sci/R&D Officer

Lou DeBergalis

Corporate Officer/Principal

Peter Sportelli

Corporate Officer/Principal

Thomas M. Edwards

Sales & Marketing

15/04/2014

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	2
Femme	1

Dont comité exécutif

Homme	2
Femme	1

Dont Administrateurs

Homme	1
Femme	0

Keryx Biopharmaceuticals, Inc. est une société biopharmaceutique axée sur le développement de médicaments pour les personnes atteintes de maladies rénales. La société est engagée dans la fabrication, le développement et la commercialisation de produits destinés à être utilisés dans le traitement de maladies humaines. Son produit commercialisé, Auryxia (citrate ferrique), qui est un médicament à base de fer, absorbable, disponible par voie orale, est approuvé aux États-Unis pour le contrôle des niveaux de phosphore sérique chez les patients atteints de maladie rénale chronique (MRC) sous dialyse. Auryxia est commercialisé au Japon sous le nom de marque Riona. Elle étudie l'utilisation du citrate ferrique pour le traitement de l'anémie ferriprive (IDA) chez les adultes non dépendants de la dialyse (NDD), IRC et NDD-IRC. Elle se concentre sur le programme Keryx Patient Plus pour faciliter l'accès des patients à Auryxia. Elle a réalisé un essai clinique de phase II et un essai clinique de phase III sur le citrate ferrique afin d'obtenir l'approbation de la Food and Drug Administration pour l'utilisation du citrate ferrique chez les patients atteints de NDD-CKD.

Employés

Secteur

Plus d'informations sur la société